SFA005

SFA005 is an orally administered small‑molecule immunomodulatory drug candidate being developed by SFA Therapeutics for the prevention and treatment of severe inflammatory lung injury associated with COVID-19, particularly cytokine storm–driven acute respiratory distress syndrome (ARDS). Preclinical development focuses on its ability to modulate inflammatory pathways triggered by lipopolysaccharide (LPS) and viral infection, with the goal of dampening excessive cytokine responses without broad immunosuppression, using mechanisms related to SFA’s microbiome‑derived, multi‑target small‑molecule platform.[3][7][9]